Today's Edition Local News Missouri News National News World Opinion Obits Sports GoMidMo Events Classifieds Jobs Newsletters Contests Search
ADVERTISEMENT
ADVERTISEMENT
story.lead_photo.caption FILE - In this June 15, 2005, file photo, a sign stands in front of a Bristol-Myers Squibb building in a Lawrence Township, N.J. Bristol-Myers Squibb is buying Celgene in a cash-and-stock deal valued at about $74 billion. (AP Photo/Mel Evans, File)

SUMMIT, N.J. (AP) — Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company’s development pipeline with cancer, immunology and cardiovascular treatments.

Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced Thursday, as well as inflammatory disease treatments and several products close to launching.

The combined company will have nine products with more than $1 billion in annual sales. Bristol’s product portfolio already includes Orencia, an injected drug for rheumatoid arthritis, and the cancer treatment Opdivo.

Bristol Chairman and CEO Giovanni Caforio said in a prepared statement the combination will create a deep product portfolio that drives growth.

It was a hard sell, however, on Wall Street. Shares of Bristol ended Thursday down $6.90, or 13.3 percent, at $45.12, on a day when the Standard & Poor’s 500 lost 2.5 percent. Celgene shares, however, soared $13.79, or 20.7 percent, to $80.43.

Under terms of the deal, shareholders of Celgene Corp., based in Summit, New Jersey, will receive one share of Bristol-Myers Squibb plus $50 in cash for each share they own. They’ll also receive one tradeable contingent value right for each Celgene share, allowing the holder to receive a $9 payment when future regulatory milestones are hit.

The cash-and-stock portion of the deal totals $102.43, based on Wednesday’s closing price of $52.43 for Bristol shares. That represents a premium of nearly 54 percent to Celgene’s closing price of $66.64.

Shareholders of Bristol-Myers Squibb Co., based in New York, would own about 69 percent of the company, with Celgene shareholders owning about 31 percent.

COMMENTS - It looks like you're using Internet Explorer, which isn't compatible with our commenting system. You can join the discussion by using another browser, like Firefox or Google Chrome.
It looks like you're using Microsoft Edge. Our commenting system is more compatible with Firefox and Google Chrome.
ADVERTISEMENT
ADVERTISEMENT